2-(Morpholin-4-yl)-1-phenylethan-1-amine → 2-Fluoro-N-(2-morpholino-1-phenylethyl)nicotinamide
반응식
[N:1]1([CH2:7][CH:8]([NH2:15])[C:9]2[CH:14]=[CH:13][CH:12]=[CH:11][CH:10]=2)[CH2:6][CH2:5][O:4][CH2:3][CH2:2]1.[F:16][C:17]1[N:32]=[CH:31][CH:30]=[CH:29][C:18]=1[C:19](NC1C=CC=CC=1C)=[O:20]>>[F:16][C:17]1[N:32]=[CH:31][CH:30]=[CH:29][C:18]=1[C:19]([NH:15][CH:8]([C:9]1[CH:10]=[CH:11][CH:12]=[CH:13][CH:14]=1)[CH2:7][N:1]1[CH2:6][CH2:5][O:4][CH2:3][CH2:2]1)=[O:20]참가 물질
3
실험 절차
2-Morpholin-4-yl-1-phenylethylamine (Array Biopharma, Inc., 0.33 g, 1.6 mmol) was converted to the desired compound (0.12 g, 87%) in a manner similar to the preparation of 2-fluoro-N-o-tolylnicotinamide (Step A of Example 8). HRMS(ESI+), 330.1618 (M+H)+ calc, 330.1620 (M+H)+ found.
출처 및 근거
- ORD 기록
- ord-b7c0b56243bf4b6882aacf455622be68
- 출처 데이터셋
- uspto-grants-2009_06
- 특허 번호